Process Development: Maximizing Process Data from Development to Manufacturing - - BioPharm International

ADVERTISEMENT

Process Development: Maximizing Process Data from Development to Manufacturing


BioPharm International
Volume 20, Issue 7

Claire Hill is a bioprocess engineer at BioPharm Services UK, Lancer House, East Street, Chesham, Bucks, HP5 1DG, United Kingdom, +44 (0) 1494.793243,

Andrew Sinclair is cofounder and managing director at BioPharm Services UK, Lancer House, East Street, Chesham, Bucks, HP5 1DG, United Kingdom, +44 (0) 1494.793243,

REFERENCES

1. Reichert JM. Trends in development and approval times for new therapeutics in the United States. Nature Reviews Drug Discovery. 2003;2(9):695–703.

2. Morris K, Venugopal S, Eckstut M. Making the most of drug development data. PharmaManufacturing 2005 Nov 30;4(10):16 –23.

3. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ 2003;22(2):151–85.

4. American National Standards Institute/Instrumentation, Systems, and Automation Society (ANSI/ISA). ANSI/ISA-88.01–1995 Batch Control Part 1: Models and terminology. Research Triangle Park, NC; 1995.

5. American National Standards Institute/Instrumentation, Systems, and Automation Society (ANSI/ISA). ANSI/ISA-88.00.03–2003 Batch Control Part 3: General and site recipe models and representation. Research Triangle Park, NC; 2003.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
FDA Develops Alternative Assay to Increase Availability of Influenza Vaccines
April 10, 2014
Merck Announes Management Changes
April 7, 2014
Author Guidelines
Source: BioPharm International,
Click here